Trump administration systematically cut deals across more than 30 industries, trading tariff relief and federal financing for corporate concessions in a pattern resembling state-driven capitalism. Companies including Pfizer, Eli Lilly, and AstraZeneca faced pressure on production location and drug …
Dr. Patrizia Cavazzoni, former head of the FDA’s Center for Drug Evaluation and Research (CDER), immediately transitioned to Pfizer as chief medical officer, reigniting intense debate about the pharmaceutical industry’s regulatory influence and the problematic ‘revolving …
Patrizia CavazzoniFDAPfizerRobert F. Kennedy Jr.Center for Drug Evaluation and Research+2 moreregulatory-capturepharmaceutical-industryfdarevolving-doorinstitutional-corruption+2 more
Pfizer announced that Dr. Scott Gottlieb, who served as FDA Commissioner from May 2017 to April 2019, would join the pharmaceutical giant’s board of directors as an independent member. The appointment came just 85 days after Gottlieb resigned from the FDA, raising immediate concerns about …
Dr. Scott GottliebFDAPfizerSenator Elizabeth Warrenregulatory-capturefdapharmaceuticalsrevolving-doorboard-appointment+1 more
Analysis of pharmaceutical industry campaign contributions from 1999-2018 revealed that the top 40 congressional recipients jointly received $45 million, with 39 serving on committees with health-related legislative jurisdiction—24 in senior positions. Of the top 20 House recipients, 17 served on …
House Energy and Commerce CommitteeFred UptonPharmaceutical Research and Manufacturers of AmericaPfizerMerckregulatory-capturecampaign-financepharmaceutical-industryhealthcarecongressional-corruption